<p>安富利制药公司（NASDAQ:AMPH - 获取免费报告）董事 Floyd Petersen 于 12 月 11 日星期四出售了 1,737 股该公司的股票。股票以平均价格 25.69 美元出售，总交易额为 44,623.53 美元。交易完成后，该董事直接持有 73,794 股公司股票，估值约为 1,895,767.86 美元。此次交易使其持股比例减少了 2.30%。该出售在向 SEC 的法律文件中披露，相关信息可通过 SEC 网站访问。</p>
<h2>安富利制药股价上涨 4.1%</h2>
<ul>
<li>在降息前值得购买的前两只小型医疗股</li>
</ul>
<p>在周一的午盘交易中，NASDAQ:AMPH 的股价上涨了 1.04 美元，达到了 26.31 美元。该公司的交易量为 472,889 股，而其平均交易量为 527,280 股。该公司的流动比率为 3.12，速动比率为 2.21，债务与股本比率为 0.78。安富利制药公司过去 12 个月的最低股价为 20.39 美元，最高股价为 42.49 美元。该公司的 50 日简单移动平均线为 25.52 美元，200 日简单移动平均线为 25.66 美元。该股票的市值为 12.1 亿美元，市盈率为 11.64，PEG 比率为 7.08，贝塔值为 0.91。</p>
<p>安富利制药（NASDAQ:AMPH - 获取免费报告）最近于 11 月 6 日星期四发布了其财报。该公司报告本季度每股收益为 0.93 美元，超出市场共识预期的 0.83 美元，超出 0.10 美元。该公司本季度的收入为 1.9184 亿美元，而分析师预期为 1.8690 亿美元。安富利制药的股本回报率为 19.70%，净利润率为 15.43%。分析师平均预测安富利制药公司本年度每股收益为 3.49 美元。</p>
<h2>分析师评级上调与下调</h2>
<ul>
<li>前景看好的小型生物科技公司安富利制药出现可操作的回调</li>
</ul>
<p>几家研究公司对 AMPH 进行了评估。巴克莱在 12 月 9 日星期二发布的报告中对安富利制药的股票进行了覆盖，给予 “持平” 评级，目标价为 30.00 美元。Needham &amp; Company LLC 在 11 月 7 日星期五的研究报告中将安富利制药的目标价从 36.00 美元下调至 34.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 12 月 8 日星期一的报告中重申了对安富利制药股票的 “持有（c）” 评级。美国银行在 8 月 26 日星期二的研究报告中将安富利制药的目标价从 28.00 美元上调至 32.00 美元，并给予该股票 “中性” 评级。最后，Zacks Research 在 11 月 14 日星期五的研究报告中将安富利制药的评级从 “强力买入” 下调至 “持有”。两位研究分析师对该股票给予 “买入” 评级，六位分析师给予该公司 “持有” 评级。根据 MarketBeat 的数据，安富利制药的共识评级为 “持有”，平均目标价为 31.00 美元。</p>
<p><strong>获取我们对安富利制药的最新分析</strong></p>
<h2>机构资金流入与流出</h2>
<p>一些对冲基金最近增加或减少了对 AMPH 的持股。FNY 投资顾问公司在第三季度收购了安富利制药的新股份，价值约为 26,000 美元。丹麦银行在第三季度购买了安富利制药的新股份，价值约为 614,000 美元。Quarry LP 在第三季度购买了安富利制药的新股份，价值约为 32,000 美元。Millennium Management LLC 在第三季度将其在安富利制药的持股增加了 12.7%。Millennium Management LLC 现在拥有 697,765 股该公司的股票，价值为 18,595,000 美元，此前在上个季度购买了额外的 78,781 股。最后，Lighthouse Investment Partners LLC 在第三季度以约 576,000 美元的价格购买了安富利制药的新股份。机构投资者持有该公司 65.09% 的股票。</p>
<h2>安富利制药公司简介</h2>
<p>（获取免费报告）</p>
<p>安富利制药公司是一家生物制药公司，在美国、中国和法国开发、生产、营销和销售仿制药和专有的注射剂、吸入剂和鼻用产品。它提供 BAQSIMI，一种用于治疗严重低血糖的鼻用喷雾剂；Primatene Mist，一种用于暂时缓解间歇性哮喘轻微症状的非处方肾上腺素吸入产品；恩诺沙班，用于预防和治疗深静脉血栓；REXTOVY 和纳洛酮用于阿片类药物过量；用于注射的急救用胰高血糖素；以及 Cortrosyn，用作筛查肾上腺皮质功能不全患者的诊断剂。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过安富利制药</li>
<li>如何计算投资回报率（ROI）</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>关注国会股票交易</li>
<li>戴尔和惠普正在涨价——投资者应注意</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在安富利制药吗？</h2>
<p>在考虑安富利制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Amphastar Pharmaceuticals 并不在名单上。</p>
<p>虽然 Amphastar Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Amphastar制药

<p>Amphastar 制药董事 Floyd Petersen 出售了 1,737 股，获得 44,623.53 美元，减少了 2.30% 的持股比例。此次出售在 SEC 文件中披露。Amphastar 的股票上涨了 4.1%，达到 26.31 美元，市值为 12.1 亿美元。分析师的评级不一，普遍持有 “持有” 评级，平均目标价为 31.00 美元。机构投资者持有 65.09% 的股份</p>

<p>Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd Petersen sold 1,737 shares of the firm's stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $25.69, for a total transaction of $44,623.53. Following the completion of the transaction, the director directly owned 73,794 shares in the company, valued at approximately $1,895,767.86. The trade was a 2.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>安富利制药公司（NASDAQ:AMPH - 获取免费报告）董事 Floyd Petersen 于 12 月 11 日星期四出售了 1,737 股该公司的股票。股票以平均价格 25.69 美元出售，总交易额为 44,623.53 美元。交易完成后，该董事直接持有 73,794 股公司股票，估值约为 1,895,767.86 美元。此次交易使其持股比例减少了 2.30%。该出售在向 SEC 的法律文件中披露，相关信息可通过 SEC 网站访问。</p>
</div><h2>Amphastar Pharmaceuticals Trading Up 4.1%</h2>
<div class="lb-trans"><h2>安富利制药股价上涨 4.1%</h2>
</div><ul>
<li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>在降息前值得购买的前两只小型医疗股</li>
</ul>
</div><p>Shares of NASDAQ:AMPH traded up $1.04 during midday trading on Monday, hitting $26.31. The company had a trading volume of 472,889 shares, compared to its average volume of 527,280. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $42.49. The firm has a fifty day simple moving average of $25.52 and a 200 day simple moving average of $25.66. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 7.08 and a beta of 0.91.</p>
<div class="lb-trans"><p>在周一的午盘交易中，NASDAQ:AMPH 的股价上涨了 1.04 美元，达到了 26.31 美元。该公司的交易量为 472,889 股，而其平均交易量为 527,280 股。该公司的流动比率为 3.12，速动比率为 2.21，债务与股本比率为 0.78。安富利制药公司过去 12 个月的最低股价为 20.39 美元，最高股价为 42.49 美元。该公司的 50 日简单移动平均线为 25.52 美元，200 日简单移动平均线为 25.66 美元。该股票的市值为 12.1 亿美元，市盈率为 11.64，PEG 比率为 7.08，贝塔值为 0.91。</p>
</div><p>Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.10. The firm had revenue of $191.84 million for the quarter, compared to analyst estimates of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%. On average, analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year.</p>
<div class="lb-trans"><p>安富利制药（NASDAQ:AMPH - 获取免费报告）最近于 11 月 6 日星期四发布了其财报。该公司报告本季度每股收益为 0.93 美元，超出市场共识预期的 0.83 美元，超出 0.10 美元。该公司本季度的收入为 1.9184 亿美元，而分析师预期为 1.8690 亿美元。安富利制药的股本回报率为 19.70%，净利润率为 15.43%。分析师平均预测安富利制药公司本年度每股收益为 3.49 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><ul>
<li>Promising Small Biotech Amphastar Sees Actionable Pullback</li>
</ul>
<div class="lb-trans"><ul>
<li>前景看好的小型生物科技公司安富利制药出现可操作的回调</li>
</ul>
</div><p>Several research firms have weighed in on AMPH. Barclays initiated coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They issued an &#34;equal weight&#34; rating and a $30.00 target price on the stock. Needham &amp; Company LLC dropped their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 8th. Bank of America increased their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, August 26th. Finally, Zacks Research lowered shares of Amphastar Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, November 14th. Two research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Amphastar Pharmaceuticals has a consensus rating of &#34;Hold&#34; and an average price target of $31.00.</p>
<div class="lb-trans"><p>几家研究公司对 AMPH 进行了评估。巴克莱在 12 月 9 日星期二发布的报告中对安富利制药的股票进行了覆盖，给予 “持平” 评级，目标价为 30.00 美元。Needham &amp; Company LLC 在 11 月 7 日星期五的研究报告中将安富利制药的目标价从 36.00 美元下调至 34.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 12 月 8 日星期一的报告中重申了对安富利制药股票的 “持有（c）” 评级。美国银行在 8 月 26 日星期二的研究报告中将安富利制药的目标价从 28.00 美元上调至 32.00 美元，并给予该股票 “中性” 评级。最后，Zacks Research 在 11 月 14 日星期五的研究报告中将安富利制药的评级从 “强力买入” 下调至 “持有”。两位研究分析师对该股票给予 “买入” 评级，六位分析师给予该公司 “持有” 评级。根据 MarketBeat 的数据，安富利制药的共识评级为 “持有”，平均目标价为 31.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on Amphastar Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对安富利制药的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in AMPH. FNY Investment Advisers LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $26,000. Danske Bank A S bought a new stake in Amphastar Pharmaceuticals during the third quarter worth about $614,000. Quarry LP bought a new stake in Amphastar Pharmaceuticals during the third quarter worth about $32,000. Millennium Management LLC boosted its position in Amphastar Pharmaceuticals by 12.7% during the third quarter. Millennium Management LLC now owns 697,765 shares of the company's stock valued at $18,595,000 after purchasing an additional 78,781 shares during the last quarter. Finally, Lighthouse Investment Partners LLC bought a new position in Amphastar Pharmaceuticals in the third quarter valued at approximately $576,000. Institutional investors own 65.09% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近增加或减少了对 AMPH 的持股。FNY 投资顾问公司在第三季度收购了安富利制药的新股份，价值约为 26,000 美元。丹麦银行在第三季度购买了安富利制药的新股份，价值约为 614,000 美元。Quarry LP 在第三季度购买了安富利制药的新股份，价值约为 32,000 美元。Millennium Management LLC 在第三季度将其在安富利制药的持股增加了 12.7%。Millennium Management LLC 现在拥有 697,765 股该公司的股票，价值为 18,595,000 美元，此前在上个季度购买了额外的 78,781 股。最后，Lighthouse Investment Partners LLC 在第三季度以约 576,000 美元的价格购买了安富利制药的新股份。机构投资者持有该公司 65.09% 的股票。</p>
</div><h2>Amphastar Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>安富利制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.</p>
<div class="lb-trans"><p>安富利制药公司是一家生物制药公司，在美国、中国和法国开发、生产、营销和销售仿制药和专有的注射剂、吸入剂和鼻用产品。它提供 BAQSIMI，一种用于治疗严重低血糖的鼻用喷雾剂；Primatene Mist，一种用于暂时缓解间歇性哮喘轻微症状的非处方肾上腺素吸入产品；恩诺沙班，用于预防和治疗深静脉血栓；REXTOVY 和纳洛酮用于阿片类药物过量；用于注射的急救用胰高血糖素；以及 Cortrosyn，用作筛查肾上腺皮质功能不全患者的诊断剂。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Amphastar Pharmaceuticals</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li>
<li>Following Congress Stock Trades</li>
<li>Dell and HP Are Raising Prices—And Investors Should Take Note</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过安富利制药</li>
<li>如何计算投资回报率（ROI）</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>关注国会股票交易</li>
<li>戴尔和惠普正在涨价——投资者应注意</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=AMPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在安富利制药吗？</h2>
</div><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安富利制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Amphastar Pharmaceuticals 并不在名单上。</p>
</div><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Amphastar Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Amphastar 制药（NASDAQ:AMPH）的一位董事出售了价值 44,623.53 美元的股票